Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Christopher Schott - JPMorgan - Analyst : Well, great. Thanks for the comments. I'm just kick off with a couple here. Maybe just starting on EYLEA HD. Can you just update us latest thinking of how that launch is progressing and just help us a little bit bridge where the 3Q results came in and what we saw from the 4Q pre-announcement today? Leonard Schleifer - Regeneron Pharmaceuticals Inc - Co-Chairman of the Board, President, Chief Executive Officer, Founder I'd be happy to do that, Chris, but I would have been happier to talk about the pipeline. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 10:15PM, REGN.OQ - Regeneron Pharmaceuticals Inc at JPMorgan Healthcare Conference

Question: Christopher Schott - JPMorgan - Analyst : Perfect. Maybe pivoting over to the pipeline. LAG-3, we're getting the melanoma data this year. I guess what do you think has enabled this much higher rate of efficacy that we seem to be seeing relative to the existing agent on the market as you think about the profile here?

Question: Christopher Schott - JPMorgan - Analyst : All right. And maybe just one last question before we wrap up here. On the Factor XI's range of indications you could pursue, should we think about the company broadly pursuing? Or are there some higher priority ones within those?

Question: Christopher Schott - JPMorgan - Analyst : Versus a one-size fits all -- Leonard Schleifer - Regeneron Pharmaceuticals Inc - Co-Chairman of the Board, President, Chief Executive Officer, Founder Thank you, Chris. And our hearts do go out to everybody in Southern California, hoping for those fires to go out.